References
- Woodward M, Rumley A, Tunstall-Pedoe H, Lowe G DO. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999; 104: 246–257
- Stamler J, Daviglus M L, Garside D B, Dyer A R, Greenland P, Neaton J D. Relationship of baseline serum cholesterol levels in three large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. J Am Med Assoc 2000; 284: 311–318
- Darling G M, Johns J A, McCloud P I, Davis S R. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337: 595–601
- Davidson M H, Testolin L M, Maki K C, von Duvillard S, Drennan K B. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997; 157: 1186–1192
- Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280: 605–613
- Ridker P, Stampfer M J, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral artery disease. J Am Med Assoc 2001; 285: 2481–2507
- Devissaguet J P, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17β-estradiol (intranasal oestradiol) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 1999; 24: 265–271
- Kauffman R F, Bryant H U. Selective estrogen receptor modulators. Drugs New Perspect 1995; 8: 531–539
- Lakoski S G, Herrington D M. Effects of estrogen receptor-active compounds on lipid metabolism. Diabetes Obes Metab 2005; 7: 471–477
- Walsh B W, Paul S, Wild R A. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85: 214–218
- Dias A R, Jr, Melo R N, Gebara O C, D'Amico E A, Nussbacher A, Halbe H W, Pinotti J A. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric 2005; 8: 63–70
- Basurto L, Saucedo R, Zarate A, Martinez C, Gaminio E, Reyes E, Hernandez M. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women. Gynecol Obstet Invest 2006; 61: 61–64
- Insull W, Jr, Davidson M H, Kulkarni P M, Siddhanti S, Ciaccia A V, Keech C A. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism 2005; 54: 939–946